Search Results - Lowe, E.

  • Showing 1 - 2 results of 2
Refine Results
  1. 1
    Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer

    Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer by Dent, R., Lindeman, G., Clemons, M., Wildiers, H., Chan, Arlene, McCarthy, N., Singer, C., Lowe, E., Watkins, C., Carmichael, J.

    Published 2013
    Get full text
  2. 2
    Substituted hippurates and hippurate analogs as substrates and inhibitors of peptidylglycine a-hydroxylating monooxygenase (PHM)

    Substituted hippurates and hippurate analogs as substrates and inhibitors of peptidylglycine a-hydroxylating monooxygenase (PHM) by Merkler, D., Asser, A., Baumgart, L., Carballo, N., Carpenter, S., Chew, G., Cosner, C., Dusi, J., Galloway, L., Lowe, Andrew, Lowe, E., King, L., Kendig, R., Kline, P., Malka, R., Merkler, K., McIntyre, N., Romero, M., Wilcox, B., Owen, T.

    Published 2008
    Get full text

Search Tools: